{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:31:41Z","timestamp":1794479501985,"version":"4.9.1"},"reference-count":172,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R35HL161185"],"award-info":[{"award-number":["R35HL161185"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cardiovasc Res"],"DOI":"10.1038\/s44161-026-00891-7","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:01:33Z","timestamp":1792746093000},"page":"1089-1102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Translational biology of human cardiac fibrosis"],"prefix":"10.1038","volume":"5","author":[{"given":"Alekhya","family":"Parvathaneni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1948-9945","authenticated-orcid":false,"given":"Kory","family":"Lavine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2505-617X","authenticated-orcid":false,"given":"James R.","family":"Priest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"891_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.stem.2016.10.004","volume":"20","author":"EE Agha","year":"2017","unstructured":"Agha, E. E. et al. Two-way conversion between lipogenic and myogenic fibroblastic phenotypes marks the progression and resolution of lung fibrosis. Cell Stem Cell 20, 261\u2013273 https:\/\/doi.org\/10.1016\/j.stem.2016.10.004 (2017).","journal-title":"Cell Stem Cell"},{"key":"891_CR2","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1164\/rccm.201212-2297OC","volume":"188","author":"C Hung","year":"2013","unstructured":"Hung, C. et al. Role of lung pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 188, 820\u2013830 https:\/\/doi.org\/10.1164\/rccm.201212-2297OC (2013).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"891_CR3","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.pccm.2024.08.003","volume":"2","author":"M Zabihi","year":"2024","unstructured":"Zabihi, M. et al. Understanding myofibroblast origin in the fibrotic lung. Chin. Med. J. Pulm. Crit. Care Med. 2, 142\u2013150 https:\/\/doi.org\/10.1016\/j.pccm.2024.08.003 (2024).","journal-title":"Chin. Med. J. Pulm. Crit. Care Med."},{"key":"891_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.stem.2014.11.004","volume":"16","author":"R Kramann","year":"2015","unstructured":"Kramann, R. et al. Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell 16, 51\u201366 https:\/\/doi.org\/10.1016\/j.stem.2014.11.004 (2015).","journal-title":"Cell Stem Cell"},{"key":"891_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41586-020-2941-1","volume":"589","author":"C Kuppe","year":"2021","unstructured":"Kuppe, C. et al. Decoding myofibroblast origins in human kidney fibrosis. Nature 589, 281\u2013286 https:\/\/doi.org\/10.1038\/s41586-020-2941-1 (2021).","journal-title":"Nature"},{"key":"891_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2353\/ajpath.2010.090517","volume":"176","author":"BD Humphreys","year":"2010","unstructured":"Humphreys, B. D. et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 176, 85\u201397 https:\/\/doi.org\/10.2353\/ajpath.2010.090517 (2010).","journal-title":"Am. J. Pathol."},{"key":"891_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3823","volume":"4","author":"I Mederacke","year":"2013","unstructured":"Mederacke, I. et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat. Commun. 4, 2823 https:\/\/doi.org\/10.1038\/ncomms3823 (2013).","journal-title":"Nat. Commun."},{"key":"891_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107245","volume":"205","author":"I Fuster-Mart\u00ednez","year":"2024","unstructured":"Fuster-Mart\u00ednez, I. & Calatayud, S. The current landscape of antifibrotic therapy across different organs: a systematic approach. Pharmacol. Res. 205, 107245 https:\/\/doi.org\/10.1016\/j.phrs.2024.107245 (2024).","journal-title":"Pharmacol. Res."},{"key":"891_CR9","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/nm1613","volume":"13","author":"EM Zeisberg","year":"2007","unstructured":"Zeisberg, E. M. et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 13, 952\u2013961 https:\/\/doi.org\/10.1038\/nm1613 (2007).","journal-title":"Nat. Med."},{"key":"891_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/01.RES.77.1.1","volume":"77","author":"LM Eisenberg","year":"1995","unstructured":"Eisenberg, L. M. & Markwald, R. R. Molecular regulation of atrioventricular valvuloseptal morphogenesis. Circ. Res. 77, 1\u20136 https:\/\/doi.org\/10.1161\/01.RES.77.1.1 (1995).","journal-title":"Circ. Res."},{"key":"891_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/aja.1001480108","volume":"148","author":"RR Markwald","year":"1977","unstructured":"Markwald, R. R., Fitzharris, T. P. & Manasek, F. J. Structural development of endocardial cushions. Am. J. Anat. 148, 85\u2013119 https:\/\/doi.org\/10.1002\/aja.1001480108 (1977).","journal-title":"Am. J. Anat."},{"key":"891_CR12","doi-asserted-by":"publisher","first-page":"18284","DOI":"10.1073\/pnas.0608799103","volume":"103","author":"SB Haudek","year":"2006","unstructured":"Haudek, S. B. et al. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc. Natl Acad. Sci. USA 103, 18284\u201318289 https:\/\/doi.org\/10.1073\/pnas.0608799103 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"891_CR13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/emboj.2011.418","volume":"31","author":"J Duan","year":"2012","unstructured":"Duan, J. et al. Wnt1\/\u03b2catenin injury response activates the epicardium and cardiac fibroblasts to promote cardiac repair. EMBO J. 31, 429\u2013442 https:\/\/doi.org\/10.1038\/emboj.2011.418 (2012).","journal-title":"EMBO J."},{"key":"891_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/CIRCRESAHA.110.233262","volume":"108","author":"JL Russell","year":"2011","unstructured":"Russell, J. L. et al. A dynamic Notch injury response activates epicardium and contributes to fibrosis-repair. Circ. Res. 108, 51\u201359 https:\/\/doi.org\/10.1161\/CIRCRESAHA.110.233262 (2011).","journal-title":"Circ. Res."},{"key":"891_CR15","doi-asserted-by":"publisher","first-page":"7556","DOI":"10.4049\/jimmunol.166.12.7556","volume":"166","author":"R Abe","year":"2001","unstructured":"Abe, R., Donnelly, S. C., Peng, T., Bucala, R. & Metz, C. N. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J. Immunol. 166, 7556\u20137562 https:\/\/doi.org\/10.4049\/jimmunol.166.12.7556 (2001).","journal-title":"J. Immunol."},{"key":"891_CR16","doi-asserted-by":"publisher","first-page":"H1363","DOI":"10.1152\/ajpheart.00395.2013","volume":"305","author":"P Kong","year":"2013","unstructured":"Kong, P., Christia, P., Saxena, A., Su, Y. & Frangogiannis, N. G. Lack of specificity of fibroblast-specific protein 1 in cardiac remodeling and fibrosis. Am. J. Physiol. Heart. Circ. Physiol. 305, H1363\u2013H1372 https:\/\/doi.org\/10.1152\/ajpheart.00395.2013 (2013).","journal-title":"Am. J. Physiol. Heart. Circ. Physiol."},{"key":"891_CR17","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1161\/CIRCULATIONAHA.111.040352","volume":"125","author":"JC Kovacic","year":"2012","unstructured":"Kovacic, J. C., Mercader, N., Torres, M., Boehm, M. & Fuster, V. Epithelial-to-mesenchymal and endothelial-to-mesenchymal transition. Circulation 125, 1795\u20131808 https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.040352 (2012).","journal-title":"Circulation"},{"key":"891_CR18","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1242\/dev.079970","volume":"139","author":"A Acharya","year":"2012","unstructured":"Acharya, A. et al. The bHLH transcription factor Tcf21 is required for lineage-specific EMT of cardiac fibroblast progenitors. Development 139, 2139\u20132149 https:\/\/doi.org\/10.1242\/dev.079970 (2012).","journal-title":"Development"},{"key":"891_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ydbio.2012.04.020","volume":"366","author":"A Wessels","year":"2012","unstructured":"Wessels, A. et al. Epicardially derived fibroblasts preferentially contribute to the parietal leaflets of the atrioventricular valves in the murine heart. Dev. Biol. 366, 111\u2013124 https:\/\/doi.org\/10.1016\/j.ydbio.2012.04.020 (2012).","journal-title":"Dev. Biol."},{"key":"891_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature06969","volume":"454","author":"CL Cai","year":"2008","unstructured":"Cai, C. L. et al. A myocardial lineage derives from Tbx18 epicardial cells. Nature 454, 104\u2013108 https:\/\/doi.org\/10.1038\/nature06969 (2008).","journal-title":"Nature"},{"key":"891_CR21","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1161\/CIRCRESAHA.119.315968","volume":"126","author":"M Nagao","year":"2020","unstructured":"Nagao, M. et al. Coronary disease associated gene TCF21 inhibits smooth muscle cell differentiation by blocking the myocardin-serum response factor pathway. Circ. Res. 126, 517\u2013529 https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.315968 (2020).","journal-title":"Circ. Res."},{"key":"891_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.yjmcc.2013.10.005","volume":"65","author":"CM Braitsch","year":"2013","unstructured":"Braitsch, C. M., Kanisicak, O., van Berlo, J. H., Molkentin, J. D. & Yutzey, K. E. Differential expression of embryonic epicardial progenitor markers and localization of cardiac fibrosis in adult ischemic injury and hypertensive heart disease. J. Mol. Cellular Cardiol. 65, 108\u2013119 https:\/\/doi.org\/10.1016\/j.yjmcc.2013.10.005 (2013).","journal-title":"J. Mol. Cellular Cardiol."},{"key":"891_CR23","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1161\/CIRCRESAHA.107.149047","volume":"101","author":"T Oka","year":"2007","unstructured":"Oka, T. et al. Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circ. Res. 101, 313\u2013321 https:\/\/doi.org\/10.1161\/CIRCRESAHA.107.149047 (2007).","journal-title":"Circ. Res."},{"key":"891_CR24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1084\/jem.20071297","volume":"205","author":"M Shimazaki","year":"2008","unstructured":"Shimazaki, M. et al. Periostin is essential for cardiac healing after acute myocardial infarction. J. Exp. Med. 205, 295\u2013303 https:\/\/doi.org\/10.1084\/jem.20071297 (2008).","journal-title":"J. Exp. Med."},{"key":"891_CR25","doi-asserted-by":"publisher","first-page":"934\u2013947","DOI":"10.1161\/CIRCRESAHA.109.201400","volume":"105","author":"P Snider","year":"2009","unstructured":"Snider, P. et al. Origin of cardiac fibroblasts and the role of periostin. Circ. Res. 105, 934\u2013947 https:\/\/doi.org\/10.1161\/CIRCRESAHA.109.201400 (2009).","journal-title":"Circ. Res."},{"key":"891_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12260","volume":"7","author":"O Kanisicak","year":"2016","unstructured":"Kanisicak, O. et al. Genetic lineage tracing defines myofibroblast origin and function in the injured heart. Nat. Commun. 7, 12260 https:\/\/doi.org\/10.1038\/ncomms12260 (2016).","journal-title":"Nat. Commun."},{"key":"891_CR27","doi-asserted-by":"publisher","unstructured":"Amrute, J. M. et al. Targeting immune\u2013fibroblast cell communication in heart failure. Nature 635, 423\u2013433 https:\/\/doi.org\/10.1038\/s41586-024-08008-5 (2024).","DOI":"10.1038\/s41586-024-08008-5"},{"key":"891_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/science.abo1984","volume":"377","author":"D Reichart","year":"2022","unstructured":"Reichart, D. et al. Pathogenic variants damage cell composition and single cell transcription in cardiomyopathies. Science 377, eabo1984 https:\/\/doi.org\/10.1126\/science.abo1984 (2022).","journal-title":"Science"},{"key":"891_CR29","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1161\/CIRCULATIONAHA.107.748053","volume":"117","author":"B Burstein","year":"2008","unstructured":"Burstein, B., Libby, E., Calderone, A. & Nattel, S. Differential behaviors of atrial versus ventricular fibroblasts. Circulation 117, 1630\u20131641 https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.748053 (2008).","journal-title":"Circulation"},{"key":"891_CR30","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1006\/jmcc.1996.0185","volume":"28","author":"AV Sigel","year":"1996","unstructured":"Sigel, A. V., Centrella, M. & Eghbali-Webb, M. Regulation of proliferative response of cardiac fibroblasts by transforming growth factor-\u03b21. J. Mol. Cellular Cardiol. 28, 1921\u20131929 https:\/\/doi.org\/10.1006\/jmcc.1996.0185 (1996).","journal-title":"J. Mol. Cellular Cardiol."},{"key":"891_CR31","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/s41588-023-01371-5","volume":"55","author":"V Nauffal","year":"2023","unstructured":"Nauffal, V. et al. Genetics of myocardial interstitial fibrosis in the human heart and association with disease. Nat. Genet. 55, 777\u2013786 https:\/\/doi.org\/10.1038\/s41588-023-01371-5 (2023).","journal-title":"Nat. Genet."},{"key":"891_CR32","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41586-022-04817-8","volume":"608","author":"M Chaffin","year":"2022","unstructured":"Chaffin, M. et al. Single-nucleus profiling of human dilated and hypertrophic cardiomyopathy. Nature 608, 174\u2013180 https:\/\/doi.org\/10.1038\/s41586-022-04817-8 (2022).","journal-title":"Nature"},{"key":"891_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk8501","volume":"10","author":"R Patrick","year":"2024","unstructured":"Patrick, R. et al. Integration mapping of cardiac fibroblast single-cell transcriptomes elucidates cellular principles of fibrosis in diverse pathologies. Sci. Adv. 10, eadk8501 https:\/\/doi.org\/10.1126\/sciadv.adk8501 (2024).","journal-title":"Sci. Adv."},{"key":"891_CR34","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s44161-025-00617-1","volume":"4","author":"G Li","year":"2025","unstructured":"Li, G. et al. Dynamic molecular atlas of cardiac fibrosis at single-cell resolution shows CD248 in cardiac fibroblasts orchestrates interactions with immune cells. Nat. Cardiovasc. Res. 4, 380\u2013396 https:\/\/doi.org\/10.1038\/s44161-025-00617-1 (2025).","journal-title":"Nat. Cardiovasc. Res."},{"key":"891_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jcmg.2017.04.006","volume":"11","author":"S Nakamori","year":"2018","unstructured":"Nakamori, S. et al. Native T1 mapping and extracellular volume mapping for the assessment of diffuse myocardial fibrosis in dilated cardiomyopathy. JACC Cardiovasc. Imaging 11, 48\u201359 https:\/\/doi.org\/10.1016\/j.jcmg.2017.04.006 (2018).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"891_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12968-016-0227-4","volume":"18","author":"SE Petersen","year":"2016","unstructured":"Petersen, S. E. et al. UK Biobank\u2019s cardiovascular magnetic resonance protocol. J. Cardiovasc. Magn. Reson. 18, 8 https:\/\/doi.org\/10.1186\/s12968-016-0227-4 (2016).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"891_CR37","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1161\/CIRCRESAHA.124.323892","volume":"134","author":"N Cadosch","year":"2024","unstructured":"Cadosch, N., Gil-Cruz, C., Perez-Shibayama, C. & Ludewig, B. Cardiac fibroblastic niches in homeostasis and inflammation. Circ. Res. 134, 1703\u20131717 https:\/\/doi.org\/10.1161\/CIRCRESAHA.124.323892 (2024).","journal-title":"Circ. Res."},{"key":"891_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abe4932","volume":"14","author":"H Abe","year":"2021","unstructured":"Abe, H. et al. NF-\u03baB activation in cardiac fibroblasts results in the recruitment of inflammatory Ly6Chi monocytes in pressure-overloaded hearts. Sci. Signal. 14, eabe4932 https:\/\/doi.org\/10.1126\/scisignal.abe4932 (2021).","journal-title":"Sci. Signal."},{"key":"891_CR39","doi-asserted-by":"publisher","first-page":"e35144","DOI":"10.1371\/journal.pone.0035144","volume":"7","author":"F Ma","year":"2012","unstructured":"Ma, F. et al. Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF \u03b2\/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS ONE 7, e35144 https:\/\/doi.org\/10.1371\/journal.pone.0035144 (2012).","journal-title":"PLoS ONE"},{"key":"891_CR40","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature24676","volume":"552","author":"S Schafer","year":"2017","unstructured":"Schafer, S. et al. IL-11 is a crucial determinant of cardiovascular fibrosis. Nature 552, 110\u2013115 https:\/\/doi.org\/10.1038\/nature24676 (2017).","journal-title":"Nature"},{"key":"891_CR41","doi-asserted-by":"publisher","first-page":"818","DOI":"10.2353\/ajpath.2007.060547","volume":"170","author":"MJ van Amerongen","year":"2007","unstructured":"van Amerongen, M. J., Harmsen, M. C., van Rooijen, N., Petersen, A. H. & van Luyn, M. J. A. Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. Am. J. Pathol. 170, 818\u2013829 https:\/\/doi.org\/10.2353\/ajpath.2007.060547 (2007).","journal-title":"Am. J. Pathol."},{"key":"891_CR42","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s44161-022-00116-7","volume":"1","author":"N Ngwenyama","year":"2022","unstructured":"Ngwenyama, N. et al. Antigen presentation by cardiac fibroblasts promotes cardiac dysfunction. Nat. Cardiovasc. Res. 1, 761\u2013774 https:\/\/doi.org\/10.1038\/s44161-022-00116-7 (2022).","journal-title":"Nat. Cardiovasc. Res."},{"key":"891_CR43","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1161\/CIRCHEARTFAILURE.115.002225","volume":"8","author":"T Nevers","year":"2015","unstructured":"Nevers, T. et al. Left ventricular T cell recruitment contributes to the pathogenesis of heart failure. Circ. Heart. Fail. 8, 776\u2013787 https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.115.002225 (2015).","journal-title":"Circ. Heart. Fail."},{"key":"891_CR44","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.regpep.2004.06.029","volume":"124","author":"T Horio","year":"2005","unstructured":"Horio, T. et al. Production and autocrine\/paracrine effects of endogenous insulin-like growth factor-1 in rat cardiac fibroblasts. Regul. Pept. 124, 65\u201372 https:\/\/doi.org\/10.1016\/j.regpep.2004.06.029 (2005).","journal-title":"Regul. Pept."},{"key":"891_CR45","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1161\/01.CIR.0000105723.91637.1C","volume":"108","author":"SL House","year":"2003","unstructured":"House, S. L. et al. Cardiac-specific overexpression of fibroblast growth factor-2 protects against myocardial dysfunction and infarction in a murine model of low-flow ischemia. Circulation 108, 3140\u20133148 https:\/\/doi.org\/10.1161\/01.CIR.0000105723.91637.1C (2003).","journal-title":"Circulation"},{"key":"891_CR46","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1172\/JCI5056","volume":"103","author":"T Matsusaka","year":"1999","unstructured":"Matsusaka, T., Katori, H., Inagami, T., Fogo, A. & Ichikawa, I. Communication between myocytes and fibroblasts in cardiac remodeling in angiotensin chimeric mice. J. Clin. Invest. 103, 1451\u20131458 https:\/\/doi.org\/10.1172\/JCI5056 (1999).","journal-title":"J. Clin. Invest."},{"key":"891_CR47","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.2353\/ajpath.2007.070003","volume":"171","author":"JAI Virag","year":"2007","unstructured":"Virag, J. A. I. et al. Fibroblast growth factor-2 regulates myocardial infarct repair. Am. J. Pathol. 171, 1431\u20131440 https:\/\/doi.org\/10.2353\/ajpath.2007.070003 (2007).","journal-title":"Am. J. Pathol."},{"key":"891_CR48","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/s0022-2828(03)00006-3","volume":"35","author":"V Chintalgattu","year":"2003","unstructured":"Chintalgattu, V., Nair, D. M. & Katwa, L. C. Cardiac myofibroblasts: a novel source of vascular endothelial growth factor (VEGF) and its receptors Flt-1 and KDR. J. Mol. Cell. Cardiol. 35, 277\u2013286 https:\/\/doi.org\/10.1016\/s0022-2828(03)00006-3 (2003).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"891_CR49","doi-asserted-by":"publisher","unstructured":"Van Linthout, S., Matz, I., Gonz\u00e1lez, A. & Davis, J. Cardiac fibroblasts in myocardial injury and heart failure. Eur. Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf902 (2026).","DOI":"10.1093\/eurheartj\/ehaf902"},{"key":"891_CR50","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41423-020-00541-3","volume":"18","author":"DM Mosser","year":"2021","unstructured":"Mosser, D. M., Hamidzadeh, K. & Goncalves, R. Macrophages and the maintenance of homeostasis. Cell Mol. Immunol. 18, 579\u2013587 https:\/\/doi.org\/10.1038\/s41423-020-00541-3 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"891_CR51","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen, S. et al. Macrophages in immunoregulation and therapeutics. Signal Transduct. Target. Ther. 8, 207 https:\/\/doi.org\/10.1038\/s41392-023-01452-1 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"891_CR52","doi-asserted-by":"publisher","first-page":"21\u201335","DOI":"10.1016\/j.immuni.2014.06.013","volume":"41","author":"S Epelman","year":"2014","unstructured":"Epelman, S., Lavine, K. J. & Randolph, G. J. Origin and functions of tissue macrophages. Immunity 41, 21\u201335 https:\/\/doi.org\/10.1016\/j.immuni.2014.06.013 (2014).","journal-title":"Immunity"},{"key":"891_CR53","doi-asserted-by":"publisher","first-page":"91\u2013104","DOI":"10.1016\/j.immuni.2013.11.019","volume":"40","author":"S Epelman","year":"2014","unstructured":"Epelman, S. et al. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Immunity 40, 91\u2013104 https:\/\/doi.org\/10.1016\/j.immuni.2013.11.019 (2014).","journal-title":"Immunity"},{"key":"891_CR54","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/s41591-018-0059-x","volume":"24","author":"G Bajpai","year":"2018","unstructured":"Bajpai, G. et al. The human heart contains distinct macrophage subsets with divergent origins and functions. Nat. Med. 24, 1234\u20131245 https:\/\/doi.org\/10.1038\/s41591-018-0059-x (2018).","journal-title":"Nat. Med."},{"key":"891_CR55","doi-asserted-by":"publisher","first-page":"263\u2013278","DOI":"10.1161\/CIRCRESAHA.118.314028","volume":"124","author":"G Bajpai","year":"2019","unstructured":"Bajpai, G. et al. Tissue resident CCR2\u2212 and CCR2+ cardiac macrophages differentially orchestrate monocyte recruitment and fate specification following myocardial injury. Circ. Res. 124, 263\u2013278 https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.314028 (2019).","journal-title":"Circ. Res."},{"key":"891_CR56","doi-asserted-by":"publisher","first-page":"16029","DOI":"10.1073\/pnas.1406508111","volume":"111","author":"KJ Lavine","year":"2014","unstructured":"Lavine, K. J. et al. Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart. Proc. Natl Acad. Sci. USA 111, 16029\u201316034 https:\/\/doi.org\/10.1073\/pnas.1406508111 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"891_CR57","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1172\/JCI94753","volume":"127","author":"H Khalil","year":"2017","unstructured":"Khalil, H. et al. Fibroblast-specific TGF-\u03b2\u2013Smad2\/3 signaling underlies cardiac fibrosis. J. Clin. Invest. 127, 3770\u20133783 https:\/\/doi.org\/10.1172\/JCI94753 (2017).","journal-title":"J. Clin. Invest."},{"key":"891_CR58","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1161\/CIRCRESAHA.109.216101","volume":"107","author":"M Dobaczewski","year":"2010","unstructured":"Dobaczewski, M. et al. Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction. Circ. Res. 107, 418\u2013428 https:\/\/doi.org\/10.1161\/CIRCRESAHA.109.216101 (2010).","journal-title":"Circ. Res."},{"key":"891_CR59","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0022-2828(91)91640-d","volume":"23","author":"M W\u00fcnsch","year":"1991","unstructured":"W\u00fcnsch, M. et al. In situ localization of transforming growth factor beta 1 in porcine heart: enhanced expression after chronic coronary artery constriction. J. Mol. Cell. Cardiol. 23, 1051\u20131062 https:\/\/doi.org\/10.1016\/0022-2828(91)91640-d (1991).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"891_CR60","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1161\/01.RES.0000163017.13772.3a","volume":"96","author":"O Dewald","year":"2005","unstructured":"Dewald, O. et al. CCL2\/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ. Res. 96, 881\u2013889 https:\/\/doi.org\/10.1161\/01.RES.0000163017.13772.3a (2005).","journal-title":"Circ. Res."},{"key":"891_CR61","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1182\/blood-2011-09-377648","volume":"119","author":"A Meyer","year":"2012","unstructured":"Meyer, A. et al. Platelet TGF-\u03b21 contributions to plasma TGF-\u03b21, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload. Blood 119, 1064\u20131074 https:\/\/doi.org\/10.1182\/blood-2011-09-377648 (2012).","journal-title":"Blood"},{"key":"891_CR62","doi-asserted-by":"publisher","first-page":"H1233","DOI":"10.1152\/ajpheart.00328.2014","volume":"307","author":"A Saxena","year":"2014","unstructured":"Saxena, A. et al. Regulatory T cells are recruited in the infarcted mouse myocardium and may modulate fibroblast phenotype and function. Am. J. Physiol. Heart. Circ. Physiol. 307, H1233\u2013H1242 https:\/\/doi.org\/10.1152\/ajpheart.00328.2014 (2014).","journal-title":"Am. J. Physiol. Heart. Circ. Physiol."},{"key":"891_CR63","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1161\/01.cir.98.7.687","volume":"98","author":"NG Frangogiannis","year":"1998","unstructured":"Frangogiannis, N. G. et al. Stem cell factor induction is associated with mast cell accumulation after canine myocardial ischemia and reperfusion. Circulation 98, 687\u2013698 https:\/\/doi.org\/10.1161\/01.cir.98.7.687 (1998).","journal-title":"Circulation"},{"key":"891_CR64","doi-asserted-by":"publisher","unstructured":"Alexanian, M. et al. Chromatin remodelling drives immune cell\u2013fibroblast communication in heart failure. Nature 635, 434\u2013443 https:\/\/doi.org\/10.1038\/s41586-024-08085-6 (2024).","DOI":"10.1038\/s41586-024-08085-6"},{"key":"891_CR65","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s41586-021-03674-1","volume":"595","author":"M Alexanian","year":"2021","unstructured":"Alexanian, M. et al. A transcriptional switch governs fibroblast activation in heart disease. Nature 595, 438\u2013443 https:\/\/doi.org\/10.1038\/s41586-021-03674-1 (2021).","journal-title":"Nature"},{"key":"891_CR66","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1172\/JCI114498","volume":"85","author":"H Loppnow","year":"1990","unstructured":"Loppnow, H. & Libby, P. Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J. Clin. Invest. 85, 731\u2013738 https:\/\/doi.org\/10.1172\/JCI114498 (1990).","journal-title":"J. Clin. Invest."},{"key":"891_CR67","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/labinvest.2016.65","volume":"96","author":"JH Wang","year":"2016","unstructured":"Wang, J. H. et al. Hypoxia-stimulated cardiac fibroblast production of IL-6 promotes myocardial fibrosis via the TGF-\u03b21 signaling pathway. Lab. Invest. 96, 839\u2013852 https:\/\/doi.org\/10.1038\/labinvest.2016.65 (2016).","journal-title":"Lab. Invest."},{"key":"891_CR68","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163799","volume":"133","author":"C Alter","year":"2023","unstructured":"Alter, C. et al. IL-6 in the infarcted heart is preferentially formed by fibroblasts and modulated by purinergic signaling. J. Clin. Invest. 133, e163799 https:\/\/doi.org\/10.1172\/JCI163799 (2023).","journal-title":"J. Clin. Invest."},{"key":"891_CR69","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1084\/jem.20161791","volume":"214","author":"T Nevers","year":"2017","unstructured":"Nevers, T. et al. Th1 effector T cells selectively orchestrate cardiac fibrosis in nonischemic heart failure. J. Exp. Med. 214, 3311\u20133329 https:\/\/doi.org\/10.1084\/jem.20161791 (2017).","journal-title":"J. Exp. Med."},{"key":"891_CR70","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s44161-022-00043-7","volume":"1","author":"SLK Bowers","year":"2022","unstructured":"Bowers, S. L. K., Meng, Q. & Molkentin, J. D. Fibroblasts orchestrate cellular crosstalk in the heart through the ECM. Nat. Cardiovasc. Res. 1, 312\u2013321 https:\/\/doi.org\/10.1038\/s44161-022-00043-7 (2022).","journal-title":"Nat. Cardiovasc. Res."},{"key":"891_CR71","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jacc.2024.10.103","volume":"85","author":"AK Barton","year":"2025","unstructured":"Barton, A. K. et al. Myocardial fibroblast activation after acute myocardial infarction. J. Am. Coll. Cardiol. 85, 578\u2013591 https:\/\/doi.org\/10.1016\/j.jacc.2024.10.103 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"891_CR72","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00259-022-05994-4","volume":"50","author":"W Song","year":"2023","unstructured":"Song, W. et al. 68Ga-FAPI PET visualize heart failure: from mechanism to clinic. Eur. J. Nucl. Med. Mol. Imaging 50, 475\u2013485 https:\/\/doi.org\/10.1007\/s00259-022-05994-4 (2023).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"891_CR73","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1007\/s12350-020-02307-w","volume":"28","author":"J Siebermair","year":"2021","unstructured":"Siebermair, J. et al. Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury\/remodeling. J. Nucl. Cardiol. 28, 812\u2013821 https:\/\/doi.org\/10.1007\/s12350-020-02307-w (2021).","journal-title":"J. Nucl. Cardiol."},{"key":"891_CR74","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2967\/jnumed.120.244673","volume":"62","author":"GS Heo","year":"2021","unstructured":"Heo, G. S. et al. Targeted PET imaging of chemokine receptor 2\u2013positive monocytes and macrophages in the injured heart. J. Nucl. Med. 62, 111\u2013114 https:\/\/doi.org\/10.2967\/jnumed.120.244673 (2021).","journal-title":"J. Nucl. Med."},{"key":"891_CR75","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1161\/CIRCRESAHA.118.314030","volume":"124","author":"GS Heo","year":"2019","unstructured":"Heo, G. S. et al. Molecular imaging visualizes recruitment of inflammatory monocytes and macrophages to the injured heart. Circ. Res. 124, 881\u2013890 https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.314030 (2019).","journal-title":"Circ. Res."},{"key":"891_CR76","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/s44161-023-00335-6","volume":"2","author":"KJ Lavine","year":"2023","unstructured":"Lavine, K. J. et al. CCR2 imaging in human ST-segment elevation myocardial infarction. Nat. Cardiovasc. Res. 2, 874\u2013880 https:\/\/doi.org\/10.1038\/s44161-023-00335-6 (2023).","journal-title":"Nat. Cardiovasc. Res."},{"key":"891_CR77","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1006\/jmcc.1996.0168","volume":"28","author":"M Brink","year":"1996","unstructured":"Brink, M. et al. Localization of the angiotensin II receptor subtypes in the human atrium. J. Mol. Cellular Cardiol. 28, 1789\u20131799 https:\/\/doi.org\/10.1006\/jmcc.1996.0168 (1996).","journal-title":"J. Mol. Cellular Cardiol."},{"key":"891_CR78","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1046\/j.1523-1755.1999.00597.x","volume":"56","author":"JM Campistol","year":"1999","unstructured":"Campistol, J. M. et al. Losartan decreases plasma levels of TGF-\u03b21 in transplant patients with chronic allograft nephropathy. Kidney Int. 56, 714\u2013719 https:\/\/doi.org\/10.1046\/j.1523-1755.1999.00597.x (1999).","journal-title":"Kidney Int."},{"key":"891_CR79","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1161\/01.CIR.0000137118.47943.5C","volume":"110","author":"MM Ciulla","year":"2004","unstructured":"Ciulla, M. M. et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis. Circulation 110, 552\u2013557 https:\/\/doi.org\/10.1161\/01.CIR.0000137118.47943.5C (2004).","journal-title":"Circulation"},{"key":"891_CR80","first-page":"171","volume":"53","author":"Y Wagatsuma","year":"2006","unstructured":"Wagatsuma, Y. et al. Clinical usefulness of the angiotensin II receptor antagonist losartan in patients with portal hypertensive gastropathy. Hepatogastroenterology 53, 171\u2013174 (2006).","journal-title":"Hepatogastroenterology"},{"key":"891_CR81","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1080\/08037050600962968","volume":"15","author":"MK Christensen","year":"2006","unstructured":"Christensen, M. K. et al. Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy. Blood Press. 15, 198\u2013206 https:\/\/doi.org\/10.1080\/08037050600962968 (2006).","journal-title":"Blood Press."},{"key":"891_CR82","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1161\/01.RES.0000150369.68826.2f","volume":"95","author":"K Chen","year":"2004","unstructured":"Chen, K., Mehta, J. L., Li, D., Joseph, L. & Joseph, J. Transforming growth factor \u03b2 Receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II. Circ. Res. 95, 1167\u20131173 https:\/\/doi.org\/10.1161\/01.RES.0000150369.68826.2f (2004).","journal-title":"Circ. Res."},{"key":"891_CR83","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1172\/JCI42028","volume":"120","author":"P Teekakirikul","year":"2010","unstructured":"Teekakirikul, P. et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires TGF-\u03b2. J. Clin. Invest. 120, 3520\u20133529 https:\/\/doi.org\/10.1172\/JCI42028 (2010).","journal-title":"J. Clin. Invest."},{"key":"891_CR84","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1161\/01.CIR.102.12.1388","volume":"102","author":"CG Brilla","year":"2000","unstructured":"Brilla, C. G., Funck, R. C. & Rupp, H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 102, 1388\u20131393 https:\/\/doi.org\/10.1161\/01.CIR.102.12.1388 (2000).","journal-title":"Circulation"},{"key":"891_CR85","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S0008-6363(97)00091-6","volume":"35","author":"RJ MacFadyen","year":"1997","unstructured":"MacFadyen, R. J., Barr, C. S. & Struthers, A. D. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res. 35, 30\u201334 https:\/\/doi.org\/10.1016\/S0008-6363(97)00091-6 (1997).","journal-title":"Cardiovasc Res."},{"key":"891_CR86","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","volume":"102","author":"F Zannad","year":"2000","unstructured":"Zannad, F., Alla, F., Dousset, B., Perez, A. & Pitt, B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation 102, 2700\u20132706 https:\/\/doi.org\/10.1161\/01.CIR.102.22.2700 (2000).","journal-title":"Circulation"},{"key":"891_CR87","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1161\/01.CIR.0000068340.96506.0F","volume":"107","author":"M Hayashi","year":"2003","unstructured":"Hayashi, M. et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 107, 2559\u20132565 https:\/\/doi.org\/10.1161\/01.CIR.0000068340.96506.0F (2003).","journal-title":"Circulation"},{"key":"891_CR88","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/clc.4960281008","volume":"28","author":"C Roongsritong","year":"2006","unstructured":"Roongsritong, C. et al. Spironolactone improves diastolic function in the elderly. Clin. Cardiol. 28, 484\u2013487 https:\/\/doi.org\/10.1002\/clc.4960281008 (2006).","journal-title":"Clin. Cardiol."},{"key":"891_CR89","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","volume":"17","author":"A Deswal","year":"2011","unstructured":"Deswal, A., Richardson, P., Bozkurt, B. & Mann, D. L. Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF). J. Card. Fail. 17, 634\u2013642 https:\/\/doi.org\/10.1016\/j.cardfail.2011.04.007 (2011).","journal-title":"J. Card. Fail."},{"key":"891_CR90","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/ehf2.14186","volume":"10","author":"L Ortega-Paz","year":"2023","unstructured":"Ortega-Paz, L. et al. Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction. ESC Heart Fail. 10, 453\u2013464 https:\/\/doi.org\/10.1002\/ehf2.14186 (2023).","journal-title":"ESC Heart Fail."},{"key":"891_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-65410-9","volume":"14","author":"K Schmidt","year":"2024","unstructured":"Schmidt, K. et al. SGLT2 inhibitors attenuate endothelial to mesenchymal transition and cardiac fibroblast activation. Sci. Rep. 14, 16459 https:\/\/doi.org\/10.1038\/s41598-024-65410-9 (2024).","journal-title":"Sci. Rep."},{"key":"891_CR92","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jcmg.2020.10.017","volume":"14","author":"T Mason","year":"2021","unstructured":"Mason, T. et al. Empagliflozin reduces myocardial extracellular volume in patients with type 2 diabetes and coronary artery disease. JACC Cardiovasc. Imaging 14, 1164\u20131173 https:\/\/doi.org\/10.1016\/j.jcmg.2020.10.017 (2021).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"891_CR93","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","volume":"9","author":"JA Requena-Ib\u00e1\u00f1ez","year":"2021","unstructured":"Requena-Ib\u00e1\u00f1ez, J. A. et al. Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF from the EMPA-TROPISM study. JACC Heart Fail. 9, 578\u2013589 https:\/\/doi.org\/10.1016\/j.jchf.2021.04.014 (2021).","journal-title":"JACC Heart Fail."},{"key":"891_CR94","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221\u20132232 https:\/\/doi.org\/10.1056\/NEJMoa2307563 (2023).","journal-title":"N. Engl. J. Med."},{"key":"891_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100679","volume":"18","author":"FB Rivera","year":"2024","unstructured":"Rivera, F. B. et al. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Am. J. Prev. Cardiol. 18, 100679 https:\/\/doi.org\/10.1016\/j.ajpc.2024.100679 (2024).","journal-title":"Am. J. Prev. Cardiol."},{"key":"891_CR96","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1210\/en.2018-00004","volume":"159","author":"LL Baggio","year":"2018","unstructured":"Baggio, L. L. et al. GLP-1 receptor expression within the human heart. Endocrinology 159, 1570\u20131584 https:\/\/doi.org\/10.1210\/en.2018-00004 (2018).","journal-title":"Endocrinology"},{"key":"891_CR97","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/aps.2016.72","volume":"37","author":"X-W Wang","year":"2016","unstructured":"Wang, X. -W. et al. Effects of linagliptin and liraglutide on glucose- and angiotensin II-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in vitro. Acta Pharmacol. Sin. 37, 1349\u20131358 https:\/\/doi.org\/10.1038\/aps.2016.72 (2016).","journal-title":"Acta Pharmacol. Sin."},{"key":"891_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109224","volume":"118","author":"T Zhao","year":"2019","unstructured":"Zhao, T. et al. Liraglutide protects high-glucose-stimulated fibroblasts by activating the CD36-JNK-AP1 pathway to downregulate P4HA1. Biomed. Pharmacother. 118, 109224 https:\/\/doi.org\/10.1016\/j.biopha.2019.109224 (2019).","journal-title":"Biomed. Pharmacother."},{"key":"891_CR99","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/jmri.27009","volume":"51","author":"EHM Paiman","year":"2020","unstructured":"Paiman, E. H. M. et al. Effect of liraglutide on cardiovascular function and myocardial tissue characteristics in type 2 diabetes patients of South Asian descent living in the Netherlands: a double-blind, randomized, placebo-controlled trial. J. Magn. Reson. Imaging 51, 1679\u20131688 https:\/\/doi.org\/10.1002\/jmri.27009 (2020).","journal-title":"J. Magn. Reson. Imaging"},{"key":"891_CR100","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12933-022-01469-w","volume":"21","author":"P Simeone","year":"2022","unstructured":"Simeone, P. et al. Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss. Cardiovasc. Diabetol. 21, 36 https:\/\/doi.org\/10.1186\/s12933-022-01469-w (2022).","journal-title":"Cardiovasc. Diabetol."},{"key":"891_CR101","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03498001 (2024)."},{"key":"891_CR102","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06499857 (2025)."},{"key":"891_CR103","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02043054 (2020)."},{"key":"891_CR104","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41591-021-01452-0","volume":"27","author":"GA Lewis","year":"2021","unstructured":"Lewis, G. A. et al. Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. Nat. Med. 27, 1477\u20131482 https:\/\/doi.org\/10.1038\/s41591-021-01452-0 (2021).","journal-title":"Nat. Med."},{"key":"891_CR105","doi-asserted-by":"publisher","unstructured":"King, T. E. J. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa1402582 (2014).","DOI":"10.1056\/NEJMoa1402582"},{"key":"891_CR106","doi-asserted-by":"publisher","first-page":"463","DOI":"10.12659\/MSM.890635","volume":"20","author":"O Sonmez","year":"2014","unstructured":"Sonmez, O. et al. Novel fibro-inflammation markers in assessing left atrial remodeling in non-valvular atrial fibrillation. Med. Sci. Monit. 20, 463\u2013470 https:\/\/doi.org\/10.12659\/MSM.890635 (2014).","journal-title":"Med. Sci. Monit."},{"key":"891_CR107","doi-asserted-by":"publisher","first-page":"qyaf068","DOI":"10.1093\/ehjimp\/qyaf068","volume":"3","author":"AWC Lee","year":"2025","unstructured":"Lee, A. W. C. et al. Is regional atrial strain a useful surrogate of regional atrial fibrosis in atrial cardiomyopathy? Eur. Heart J. Imaging Methods Pract. 3, qyaf068 https:\/\/doi.org\/10.1093\/ehjimp\/qyaf068 (2025).","journal-title":"Eur. Heart J. Imaging Methods Pract."},{"key":"891_CR108","doi-asserted-by":"publisher","unstructured":"Takafuji, M. et al. Left atrial and ventricular strain and extracellular volume fraction in patients with paroxysmal and persistent atrial fibrillation. Int. J. Cardiovasc. Imaging https:\/\/doi.org\/10.1007\/s10554-025-03443-5 (2025).","DOI":"10.1007\/s10554-025-03443-5"},{"key":"891_CR109","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/0886022X.2022.2044351","volume":"44","author":"C Feiteng","year":"2022","unstructured":"Feiteng, C. et al. Relaxin inhibits renal fibrosis and the epithelial-to-mesenchymal transition via the Wnt\/\u03b2-catenin signaling pathway. Ren. Fail. 44, 513\u2013524 https:\/\/doi.org\/10.1080\/0886022X.2022.2044351 (2022).","journal-title":"Ren. Fail."},{"key":"891_CR110","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1161\/HYPERTENSIONAHA.114.03594","volume":"64","author":"CS Samuel","year":"2014","unstructured":"Samuel, C. S. et al. Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease. Hypertension 64, 315\u2013322 https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.03594 (2014).","journal-title":"Hypertension"},{"key":"891_CR111","doi-asserted-by":"publisher","first-page":"e63896","DOI":"10.1371\/journal.pone.0063896","volume":"8","author":"C Sassoli","year":"2013","unstructured":"Sassoli, C. et al. Relaxin prevents cardiac fibroblast-myofibroblast transition via Notch-1-mediated inhibition of TGF-\u03b2\/Smad3 signaling. PLoS ONE 8, e63896 https:\/\/doi.org\/10.1371\/journal.pone.0063896 (2013).","journal-title":"PLoS ONE"},{"key":"891_CR112","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.mce.2007.09.008","volume":"280","author":"RAD Bathgate","year":"2008","unstructured":"Bathgate, R. A. D. et al. Adenovirus-mediated delivery of relaxin reverses cardiac fibrosis. Mol. Cell. Endocrinol. 280, 30\u201338 https:\/\/doi.org\/10.1016\/j.mce.2007.09.008 (2008).","journal-title":"Mol. Cell. Endocrinol."},{"key":"891_CR113","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","volume":"381","author":"JR Teerlink","year":"2013","unstructured":"Teerlink, J. R. et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381, 29\u201339 https:\/\/doi.org\/10.1016\/S0140-6736(12)61855-8 (2013).","journal-title":"Lancet"},{"key":"891_CR114","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1056\/NEJMoa1801291","volume":"381","author":"M Metra","year":"2019","unstructured":"Metra, M. et al. Effects of serelaxin in patients with acute heart failure. N. Engl. J. Med. 381, 716\u2013726 https:\/\/doi.org\/10.1056\/NEJMoa1801291 (2019).","journal-title":"N. Engl. J. Med."},{"key":"891_CR115","doi-asserted-by":"publisher","unstructured":"Voors, A. A. et al. End-organ protective effect of serelaxin in patients hospitalized for heart failure: results of the biomarker substudy of Relaxin in Acute Heart Failure-2 (RELAX-AHF-2). Eur. J. Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.3551 (2025).","DOI":"10.1002\/ejhf.3551"},{"key":"891_CR116","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/j.jchf.2024.04.028","volume":"12","author":"KA Gomez","year":"2024","unstructured":"Gomez, K. A. et al. Distinct comorbidity clusters in patients with acute heart failure. JACC Heart Fail. 12, 1762\u20131774 https:\/\/doi.org\/10.1016\/j.jchf.2024.04.028 (2024).","journal-title":"JACC Heart Fail."},{"key":"891_CR117","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1016\/j.jacc.2021.04.028","volume":"77","author":"R Hinkel","year":"2021","unstructured":"Hinkel, R. et al. AntimiR-132 attenuates myocardial hypertrophy in an animal model of percutaneous aortic constriction. J. Am. Coll. Cardiol. 77, 2923\u20132935 https:\/\/doi.org\/10.1016\/j.jacc.2021.04.028 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"891_CR118","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/eurheartj\/ehaa791","volume":"42","author":"S Batkai","year":"2020","unstructured":"Batkai, S. et al. CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure. Eur. Heart J. 42, 192\u2013201 https:\/\/doi.org\/10.1093\/eurheartj\/ehaa791 (2020).","journal-title":"Eur. Heart J."},{"key":"891_CR119","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/ejhf.961","volume":"20","author":"S Masson","year":"2018","unstructured":"Masson, S. et al. Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure. Eur. J. Heart Fail. 20, 78\u201385 https:\/\/doi.org\/10.1002\/ejhf.961 (2018).","journal-title":"Eur. J. Heart Fail."},{"key":"891_CR120","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/eurheartj\/ehaa898","volume":"42","author":"J T\u00e4ubel","year":"2020","unstructured":"T\u00e4ubel, J. et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. Eur. Heart J. 42, 178\u2013188 https:\/\/doi.org\/10.1093\/eurheartj\/ehaa898 (2020).","journal-title":"Eur. Heart J."},{"key":"891_CR121","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/ejhf.3139","volume":"26","author":"J Bauersachs","year":"2024","unstructured":"Bauersachs, J. et al. Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF-REVERT trial. Eur. J. Heart Fail. 26, 674\u2013682 https:\/\/doi.org\/10.1002\/ejhf.3139 (2024).","journal-title":"Eur. J. Heart Fail."},{"key":"891_CR122","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","volume":"573","author":"H Aghajanian","year":"2019","unstructured":"Aghajanian, H. et al. Targeting cardiac fibrosis with engineered T cells. Nature 573, 430\u2013433 https:\/\/doi.org\/10.1038\/s41586-019-1546-z (2019).","journal-title":"Nature"},{"key":"891_CR123","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nm827","volume":"9","author":"RJ Brentjens","year":"2003","unstructured":"Brentjens, R. J. et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9, 279\u2013286 https:\/\/doi.org\/10.1038\/nm827 (2003).","journal-title":"Nat. Med."},{"key":"891_CR124","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/j.ymthe.2019.09.021","volume":"27","author":"RJ Vagnozzi","year":"2019","unstructured":"Vagnozzi, R. J., Johansen, A. K. Z. & Molkentin, J. D. CARdiac immunotherapy: T cells engineered to treat the fibrotic heart. Mol. Ther. 27, 1869\u20131871 https:\/\/doi.org\/10.1016\/j.ymthe.2019.09.021 (2019).","journal-title":"Mol. Ther."},{"key":"891_CR125","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.3955","volume":"42","author":"AME Abdalla","year":"2024","unstructured":"Abdalla, A. M. E., Miao, Y., Ahmed, A. I. M., Meng, N. & Ouyang, C. CAR-T cell therapeutic avenue for fighting cardiac fibrosis: roadblocks and perspectives. Cell Biochem. Funct. 42, e3955 https:\/\/doi.org\/10.1002\/cbf.3955 (2024).","journal-title":"Cell Biochem. Funct."},{"key":"891_CR126","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/cvr\/cvaa324","volume":"117","author":"NG Frangogiannis","year":"2021","unstructured":"Frangogiannis, N. G. Cardiac fibrosis. Cardiovasc. Res. 117, 1450\u20131488 https:\/\/doi.org\/10.1093\/cvr\/cvaa324 (2021).","journal-title":"Cardiovasc. Res."},{"key":"891_CR127","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u201396 https:\/\/doi.org\/10.1126\/science.abm0594 (2022).","journal-title":"Science"},{"key":"891_CR128","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1200\/JCO.2015.64.9970","volume":"34","author":"NC Smits","year":"2016","unstructured":"Smits, N. C. & Sentman, C. L. Bispecific T-cell engagers (BiTEs) as treatment of B-cell lymphoma. J. Clin. Oncol. 34, 1131\u20131133 https:\/\/doi.org\/10.1200\/JCO.2015.64.9970 (2016).","journal-title":"J. Clin. Oncol."},{"key":"891_CR129","doi-asserted-by":"publisher","first-page":"6852","DOI":"10.1158\/0008-5472.CAN-18-1750","volume":"78","author":"JD Freedman","year":"2018","unstructured":"Freedman, J. D. et al. An oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells. Cancer Res. 78, 6852\u20136865 https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-1750 (2018).","journal-title":"Cancer Res."},{"key":"891_CR130","doi-asserted-by":"publisher","unstructured":"Amrute, J. M. et al. Targeting modulated vascular smooth muscle cells in atherosclerosis via FAP-directed immunotherapy. Science 392, https:\/\/doi.org\/10.1126\/science.adx1736 (2026).","DOI":"10.1126\/science.adx1736"},{"key":"891_CR131","doi-asserted-by":"publisher","first-page":"7143","DOI":"10.1016\/j.cell.2024.09.034","volume":"187","author":"H Zhang","year":"2024","unstructured":"Zhang, H. et al. Multiscale drug screening for cardiac fibrosis identifies MD2 as a therapeutic target. Cell 187, 7143\u20137163 https:\/\/doi.org\/10.1016\/j.cell.2024.09.034 (2024).","journal-title":"Cell"},{"key":"891_CR132","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1164\/rccm.201510-1955OC","volume":"194","author":"LM Yung","year":"2016","unstructured":"Yung, L. M. et al. A selective transforming growth factor-\u03b2 ligand trap attenuates pulmonary hypertension. Am. J. Respir. Crit. Care Med. 194, 1140\u20131151 https:\/\/doi.org\/10.1164\/rccm.201510-1955OC (2016).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"891_CR133","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aai9118","volume":"9","author":"R Micheletti","year":"2017","unstructured":"Micheletti, R. et al. The long noncoding RNA Wisper controls cardiac fibrosis and remodeling. Sci. Transl. Med. 9, eaai9118 https:\/\/doi.org\/10.1126\/scitranslmed.aai9118 (2017).","journal-title":"Sci. Transl. Med."},{"key":"891_CR134","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00441-011-1241-3","volume":"347","author":"T Doetschman","year":"2012","unstructured":"Doetschman, T. et al. Transforming growth factor beta signaling in adult cardiovascular diseases and repair. Cell Tissue Res. 347, 203\u2013223 https:\/\/doi.org\/10.1007\/s00441-011-1241-3 (2012).","journal-title":"Cell Tissue Res."},{"key":"891_CR135","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.yjmcc.2014.08.008","volume":"76","author":"KVT Engebretsen","year":"2014","unstructured":"Engebretsen, K. V. T. et al. Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5. J. Mol. Cell. Cardiol. 76, 148\u2013157 https:\/\/doi.org\/10.1016\/j.yjmcc.2014.08.008 (2014).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"891_CR136","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1177\/0192623311416259","volume":"39","author":"MJ Anderton","year":"2011","unstructured":"Anderton, M. J. et al. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol. Pathol. 39, 916\u2013924 https:\/\/doi.org\/10.1177\/0192623311416259 (2011).","journal-title":"Toxicol. Pathol."},{"key":"891_CR137","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s12012-014-9297-4","volume":"15","author":"RJ Kovacs","year":"2015","unstructured":"Kovacs, R. J. et al. Cardiac safety of TGF-\u03b2 receptor I kinase inhibitor LY2157299 monohydrate in cancer patients in a first-in-human dose study. Cardiovasc. Toxicol. 15, 309\u2013323 https:\/\/doi.org\/10.1007\/s12012-014-9297-4 (2015).","journal-title":"Cardiovasc. Toxicol."},{"key":"891_CR138","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1161\/CIRCRESAHA.114.302653","volume":"114","author":"PP Rainer","year":"2014","unstructured":"Rainer, P. P. et al. Cardiomyocyte-specific transforming growth factor \u03b2 suppression blocks neutrophil infiltration, augments multiple cytoprotective cascades, and reduces early mortality after myocardial infarction. Circ. Res. 114, 1246\u20131257 https:\/\/doi.org\/10.1161\/CIRCRESAHA.114.302653 (2014).","journal-title":"Circ. Res."},{"key":"891_CR139","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1161\/CIRCULATIONAHA.123.064155","volume":"148","author":"L Alex","year":"2023","unstructured":"Alex, L. et al. Cardiac pericytes acquire a fibrogenic phenotype and contribute to vascular maturation after myocardial infarction. Circulation 148, 882\u2013898 https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.064155 (2023).","journal-title":"Circulation"},{"key":"891_CR140","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41568-025-00819-6","volume":"25","author":"MH Barcellos-Hoff","year":"2025","unstructured":"Barcellos-Hoff, M. H. & Yom, S. S. Revisiting the TGF\u03b2 paradox: insights from HPV-driven cancer and the DNA damage response. Nat. Rev. Cancer 25, 534\u2013544 https:\/\/doi.org\/10.1038\/s41568-025-00819-6 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"891_CR141","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.124.017174","volume":"18","author":"J Wang","year":"2025","unstructured":"Wang, J. et al. Prognostic value of myocardial T1 mapping for predicting adverse events in hypertrophic cardiomyopathy. Circ. Cardiovas. Imaging 18, e017174 https:\/\/doi.org\/10.1161\/CIRCIMAGING.124.017174 (2025).","journal-title":"Circ. Cardiovas. Imaging"},{"key":"891_CR142","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/ehjci\/jeae260","volume":"26","author":"Z Ashkir","year":"2024","unstructured":"Ashkir, Z. et al. Myocardial disarray and fibrosis across hypertrophic cardiomyopathy stages associate with ECG markers of arrhythmic risk. Eur. Heart J. Cardiovasc. Imaging 26, 218\u2013228 https:\/\/doi.org\/10.1093\/ehjci\/jeae260 (2024).","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"891_CR143","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1161\/CIRCHEARTFAILURE.110.960716","volume":"4","author":"H Krum","year":"2011","unstructured":"Krum, H. et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction. Circ. Heart Fail. 4, 561\u2013568 https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.110.960716 (2011).","journal-title":"Circ. Heart Fail."},{"key":"891_CR144","doi-asserted-by":"publisher","first-page":"578","DOI":"10.21037\/cdt.2019.12.03","volume":"9","author":"S Li","year":"2019","unstructured":"Li, S. et al. Left ventricular fibrosis by extracellular volume fraction and the risk of atrial fibrillation recurrence after catheter ablation. Cardiovasc. Diagn. Ther. 9, 578\u2013585 https:\/\/doi.org\/10.21037\/cdt.2019.12.03 (2019).","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"891_CR145","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/ehjci\/jeac242","volume":"24","author":"AK Barton","year":"2023","unstructured":"Barton, A. K. et al. Emerging molecular imaging targets and tools for myocardial fibrosis detection. Eur. Heart J. Cardiovasc. Imaging 24, 261\u2013275 https:\/\/doi.org\/10.1093\/ehjci\/jeac242 (2023).","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"891_CR146","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1093\/infdis\/jiz184","volume":"221","author":"MV Zanni","year":"2020","unstructured":"Zanni, M. V. et al. Immune correlates of diffuse myocardial fibrosis and diastolic dysfunction among aging women with human immunodeficiency virus. J. Infect. Dis. 221, 1315\u20131320 https:\/\/doi.org\/10.1093\/infdis\/jiz184 (2020).","journal-title":"J. Infect. Dis."},{"key":"891_CR147","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.jacc.2008.06.049","volume":"52","author":"L Iles","year":"2008","unstructured":"Iles, L. et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J. Am. Coll. Cardiol. 52, 1574\u20131580 https:\/\/doi.org\/10.1016\/j.jacc.2008.06.049 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"891_CR148","first-page":"176","volume":"29","author":"JM Wilson","year":"2002","unstructured":"Wilson, J. M. et al. Magnetic resonance imaging of myocardial fibrosis in hypertrophic cardiomyopathy. Tex. Heart Inst. J. 29, 176\u2013180 (2002).","journal-title":"Tex. Heart Inst. J."},{"key":"891_CR149","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1161\/01.cir.81.1.58","volume":"81","author":"E Picano","year":"1990","unstructured":"Picano, E. et al. In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans. Circulation 81, 58\u201364 https:\/\/doi.org\/10.1161\/01.cir.81.1.58 (1990).","journal-title":"Circulation"},{"key":"891_CR150","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.clinbiochem.2010.02.002","volume":"43","author":"B Dieplinger","year":"2010","unstructured":"Dieplinger, B. et al. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin. Biochem. 43, 714\u2013719 https:\/\/doi.org\/10.1016\/j.clinbiochem.2010.02.002 (2010).","journal-title":"Clin. Biochem."},{"key":"891_CR151","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.ejheart.2008.09.010","volume":"10","author":"JL Bj\u00f8rnstad","year":"2008","unstructured":"Bj\u00f8rnstad, J. L. et al. Alterations in circulating activin A, GDF-15, TGF-beta3 and MMP-2, -3, and -9 during one year of left ventricular reverse remodelling in patients operated for severe aortic stenosis. Eur. J. Heart Fail. 10, 1201\u20131207 https:\/\/doi.org\/10.1016\/j.ejheart.2008.09.010 (2008).","journal-title":"Eur. J. Heart Fail."},{"key":"891_CR152","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3109\/07853890.2010.538080","volume":"43","author":"RA de Boer","year":"2011","unstructured":"de Boer, R. A. et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann. Med. 43, 60\u201368 https:\/\/doi.org\/10.3109\/07853890.2010.538080 (2011).","journal-title":"Ann. Med."},{"key":"891_CR153","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1006\/jmcc.1999.1052","volume":"32","author":"L Roten","year":"2000","unstructured":"Roten, L. et al. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. J. Mol. Cell. Cardiol. 32, 109\u2013120 https:\/\/doi.org\/10.1006\/jmcc.1999.1052 (2000).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"891_CR154","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1161\/01.cir.101.14.1729","volume":"101","author":"R Querejeta","year":"2000","unstructured":"Querejeta, R. et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 101, 1729\u20131735 https:\/\/doi.org\/10.1161\/01.cir.101.14.1729 (2000).","journal-title":"Circulation"},{"key":"891_CR155","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1161\/01.hyp.0000024573.17293.23","volume":"40","author":"MM Lindsay","year":"2002","unstructured":"Lindsay, M. M., Maxwell, P. & Dunn, F. G. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 40, 136\u2013141 https:\/\/doi.org\/10.1161\/01.hyp.0000024573.17293.23 (2002).","journal-title":"Hypertension"},{"key":"891_CR156","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1373\/clinchem.2006.076828","volume":"53","author":"T Kempf","year":"2007","unstructured":"Kempf, T. et al. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin. Chem. 53, 284\u2013291 https:\/\/doi.org\/10.1373\/clinchem.2006.076828 (2007).","journal-title":"Clin. Chem."},{"key":"891_CR157","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1253\/circj.69.1244","volume":"69","author":"H Kawano","year":"2005","unstructured":"Kawano, H. et al. Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy. Circ. J. 69, 1244\u20131248 https:\/\/doi.org\/10.1253\/circj.69.1244 (2005).","journal-title":"Circ. J."},{"key":"891_CR158","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.2967\/jnumed.107.043075","volume":"48","author":"S Kasama","year":"2007","unstructured":"Kasama, S. et al. Long-term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acute myocardial infarction. J. Nucl. Med. 48, 1676\u20131682 https:\/\/doi.org\/10.2967\/jnumed.107.043075 (2007).","journal-title":"J. Nucl. Med."},{"key":"891_CR159","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jsams.2009.08.001","volume":"13","author":"VA Cornelissen","year":"2010","unstructured":"Cornelissen, V. A., Fagard, R. H. & Lijnen, P. J. Serum collagen-derived peptides are unaffected by physical training in older sedentary subjects. J. Sci. Med. Sport 13, 424\u2013428 https:\/\/doi.org\/10.1016\/j.jsams.2009.08.001 (2010).","journal-title":"J. Sci. Med. Sport"},{"key":"891_CR160","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ijcard.2009.12.028","volume":"146","author":"E Ashton","year":"2011","unstructured":"Ashton, E. et al. Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study. Int. J. Cardiol. 146, 404\u2013407 https:\/\/doi.org\/10.1016\/j.ijcard.2009.12.028 (2011).","journal-title":"Int. J. Cardiol."},{"key":"891_CR161","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1291\/hypres.28.787","volume":"28","author":"Y Shibasaki","year":"2005","unstructured":"Shibasaki, Y. et al. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertens. Res. 28, 787\u2013795 https:\/\/doi.org\/10.1291\/hypres.28.787 (2005).","journal-title":"Hypertens. Res."},{"key":"891_CR162","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"B Dahl\u00f6f","year":"2005","unstructured":"Dahl\u00f6f, B. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366, 895\u2013906 https:\/\/doi.org\/10.1016\/S0140-6736(05)67185-1 (2005).","journal-title":"Lancet"},{"key":"891_CR163","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1093\/eurjhf\/hfr151","volume":"14","author":"N Lopez-Andr\u00e8s","year":"2012","unstructured":"Lopez-Andr\u00e8s, N. et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur. J. Heart Fail. 14, 74\u201381 https:\/\/doi.org\/10.1093\/eurjhf\/hfr151 (2012).","journal-title":"Eur. J. Heart Fail."},{"key":"891_CR164","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.clinthera.2011.11.002","volume":"34","author":"E Abulhul","year":"2012","unstructured":"Abulhul, E. et al. Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide. Clin. Ther. 34, 91\u2013100 https:\/\/doi.org\/10.1016\/j.clinthera.2011.11.002 (2012).","journal-title":"Clin. Ther."},{"key":"891_CR165","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00392-017-1157-3","volume":"107","author":"JP Ferreira","year":"2018","unstructured":"Ferreira, J. P. et al. Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study. Clin. Res. Cardiol. 107, 49\u201359 https:\/\/doi.org\/10.1007\/s00392-017-1157-3 (2018).","journal-title":"Clin. Res. Cardiol."},{"key":"891_CR166","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jacc.2018.11.042","volume":"73","author":"MR Zile","year":"2019","unstructured":"Zile, M. R. et al. Effects of sacubitril\/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF. J. Am. Coll. Cardiol. 73, 795\u2013806 https:\/\/doi.org\/10.1016\/j.jacc.2018.11.042 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"891_CR167","doi-asserted-by":"publisher","first-page":"e004446","DOI":"10.1161\/CIRCHEARTFAILURE.117.004446","volume":"11","author":"E O\u2019Meara","year":"2018","unstructured":"O\u2019Meara, E. et al. Independent prognostic value of serum soluble ST2 measurements in patients with heart failure and reduced ejection fraction in the PARADIGM-HF Trial (prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure). Circ. Heart Fail. 11, e004446 https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.117.004446 (2018).","journal-title":"Circ. Heart Fail."},{"key":"891_CR168","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1161\/CIRCULATIONAHA.115.019949","volume":"134","author":"B Heydari","year":"2016","unstructured":"Heydari, B. et al. Effect of omega-3 acid ethyl esters on left ventricular remodeling after acute myocardial infarction: the OMEGA-REMODEL randomized clinical trial. Circulation 134, 378\u2013391 https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.019949 (2016).","journal-title":"Circulation"},{"key":"891_CR169","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1161\/CIRCULATIONAHA.111.063412","volume":"125","author":"E Giannetta","year":"2012","unstructured":"Giannetta, E. et al. Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation 125, 2323\u20132333 https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.063412 (2012).","journal-title":"Circulation"},{"key":"891_CR170","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01971593 (2018)."},{"key":"891_CR171","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02251431 (2026)."},{"key":"891_CR172","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.3390\/jcm8111834","volume":"8","author":"P Pollesello","year":"2019","unstructured":"Pollesello, P. et al. Short-term therapies for treatment of acute and advanced heart failure\u2014why so few drugs available in clinical use, why even fewer in the pipeline? J. Clin. Med. 8, 1834 https:\/\/doi.org\/10.3390\/jcm8111834 (2019).","journal-title":"J. Clin. Med."}],"container-title":["Nature Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00891-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00891-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00891-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:07:09Z","timestamp":1794478029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00891-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":172,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["891"],"URL":"https:\/\/doi.org\/10.1038\/s44161-026-00891-7","relation":{},"ISSN":["2731-0590"],"issn-type":[{"value":"2731-0590","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.R.P. is a shareholder of Tenaya Therapeutics, Cytokinetics and insitro. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}